Category: St. Jude Medical
Covidien said it's pulling the plug on its OneShot renal denervation device, citing the slow development of the hypertension market.
Covidien (NYSE:COV) said it plans to wind down its OneShot renal denervation program, largely due to "slower than expected development of the renal denervation market," meaning the end for a U.S. clinical trial of the high blood pressure device.
Cardiologist Dr. Darrel Francis finds himself attempting once again to drag the conversation back from the edge of hyperbole as the market reacts to the lackluster outcome of Medtronic's highly anticipated Symplicity HTN-3 trial of renal denervation in treatment of hypertension.
St. Jude Medical quietly accepts FDA premarket approval for its Cool Flex ablation catheter and ablation generator for treatment of arrhythmia.
Medtech titan St. Jude Medical (NYSE:STJ) won FDA premarket approval for its Cool Flex cardiac ablation system with indication to treat irregular heart rhythms.
Medtronic's clinical trial flop may signal the end for renal denervation in treating hypertension, according to a co-principal investigator in Medtronic's SYMPLICITY HTN-3 trial.
The future of renal denervation in treatment of hypertension is shaky at best, according to 1 of the principal investigators involved with Medtronic's disappointing clinical trial.
In case you couldn't make it to sunny San Francisco, here are some of the best medical device stories that came out of the J.P. Morgan Healthcare conference this week.
Boston Scientific CEO Mike Mahoney says the company is still bullish on the prospects for its Vessix renal denervation platform for treating high blood pressure, despite the efficacy failure of Medtronic's gold-standard Symplicity HTN-3 trial.
St. Jude Medical president & CEO Dan Starks says that rival Medtronic's failed renal denervation study is no reason to stop pursuing the technology in treatment of hypertension.